HopeStage
Back to all studies
CompletedNCT00579280

Quetiapine, divalproex, or placebo for anxiety in bipolarity

About this title

Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD

Read the official source — NCT00579280
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Palo Alto and 2 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2007
Recruitment status
Completed
Enrollment listed in the registry
224
Sponsor
University of South Florida
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00579280
Official title
Show the full official title

A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Palo Alto · Tampa · Cincinnati

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of South Florida, a university.

Did this study involve medication?

Yes. The study involved medication, including quetiapine SR, divalproex sodium ER and placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies